Skip to content
The Policy VaultThe Policy Vault

Tibsovo (ivosidenib) — Medica

Chondrosarcoma (Bone Cancer)

Initial criteria

  • Patient has chondrosarcoma
  • Patient has isocitrate dehydrogenase-1 (IDH1) mutation-positive disease

Approval duration

1 year